Physician profile
Mark A Garza
NPI 1548436934
$5,246.36
in general payments reported to CMS, 2019-2025
44 companies · $596 in 2025
The $596 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $424 · 2021: $1,009 · 2022: $886 · 2023: $1,012 · 2024: $834 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020 · Travel and Lodging: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.78 |
| Travel and Lodging | $422.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $775.52 | 2019-2025 | Relistor, Trulance |
| Pacira Pharmaceuticals Incorporated | $556.08 | 2023 | Iovera |
| Collegium Pharmaceutical, INC. | $479.56 | 2019-2025 | Belbuca |
| Abbvie INC. | $421.57 | 2021-2023 | |
| Medtronic, INC. | $363.52 | 2022-2024 | Synchromedii, Intellis Adaptivestim |
| Scilex Pharmaceuticals INC. | $261.27 | 2019-2024 | Ztlido |
| Amgen INC. | $229.77 | 2020-2022 | |
| Si-Bone, INC. | $222.81 | 2020-2021 | |
| Forte Bio-Pharma LLC | $174.30 | 2025 | Prolate, Tanlor, Nalocet |
| Vertex Pharmaceuticals Incorporated | $160.94 | 2024-2025 | |
| Horizon Therapeutics Plc | $141.15 | 2022 | |
| Pfizer INC. | $125.84 | 2019-2025 | |
| Boston Scientific Corporation | $102.14 | 2019-2022 | |
| Mml US, INC. | $101.40 | 2023 | Reactiv8 |
| Arbor Pharmaceuticals, INC. | $92.24 | 2020-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Garza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.